Kancera AB engages in the research, development, and sale of drug candidates to pharmaceutical companies. It focuses on Fractalkine program which develops a candidate drugs for treatment of severe inflammatory diseases and cancer. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Revenue and Earnings forecasts and estimates accuracy
Dividend yield, history and sustainability
Financial position and solvency of the company